CGRP antagonists for decreasing migraine frequency: New options, long overdue.
Where this comes from
- Record sourced from PubMed, PMID 32238376.
- Also identified by DOI 10.3949/ccjm.87a.19048.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The cornerstone of preventive migraine treatment has long been drugs developed for other diseases such as epilepsy, depression, and hypertension. But a new set of drugs is available for preventing migraine attacks: erenumab, galcanezumab, fremanezumab, and eptinezumab. These monoclonal antibodies target calcitonin gene-related peptide (CGRP) or its receptors, each a key molecule in the pathophysiology of migraine.
Medical subject headings
- Calcitonin Gene-Related Peptide
- Migraine Disorders